SEPN
Septerna, Inc.26.23
-0.95-3.5%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.17BP/E (TTM)
-Basic EPS (TTM)
-6.90Dividend Yield
0%Recent Filings
8-K
SEP-479 selected; cash $562M
Septerna selected SEP-479 as its next-generation oral PTH1R agonist for hypoparathyroidism, showing dose-dependent calcium boosts in monkey studies, with Phase 1 slated for H1 2026. SEP-631's Phase 1 in healthy volunteers advances for mast cell diseases, data due H1 2026. Cash hit $561.6M, funding ops into 2029; Q3 swung to $8.2M net income on $21.5M revenue. Pipeline momentum builds.
10-Q
Q3 FY2025 results
Septerna swung to a $8.2M net profit in Q3 ended September 30, 2025, on $21.5M revenue (up from $0.2M y/y)—mostly Novo collab recognition—versus Q2's $24.8M loss; nine-month net loss narrowed to $38.1M from $51.1M y/y as YTD revenue hit $21.8M. A $12.5M Vertex milestone gain offset higher R&D spend, while $14.2M interest income boosted the bottom line; diluted EPS of $0.18 tracks 45.6M shares. Cash swelled to $320M with $562M total liquidity, fueled by $125M operating cash flow from $195M Novo upfront. Revenue hinges on collab milestones. Government shutdowns risk FDA delays.
8-K
Septerna appoints biotech leader to board
Septerna expanded its board to eight members on September 25, 2025, appointing Keith Gottesdiener, M.D., a biotech veteran with over 30 years advancing therapies from discovery to approval, as a Class I director. Effective September 26, he joins the Compensation Committee and chairs the new R&D Committee, bringing expertise in regulatory strategy and clinical development to guide Septerna's GPCR pipeline, including the PTH1R program for hypoparathyroidism. His addition bolsters oversight at this pivotal stage. Yet risks in clinical trials persist.
8-K
Septerna pipeline updates
Septerna updated its corporate presentation on September 3, 2025, highlighting pipeline progress in GPCR-targeted oral small molecules. SEP-631's Phase 1 trial in healthy volunteers kicked off in August 2025, with initial safety and efficacy data due in the first half of 2026; SEP-479 advances toward Phase 1 initiation then too, after preclinical success normalizing calcium in hypoparathyroidism models. Backed by a Novo Nordisk collaboration yielding $195 million upfront, cash funds operations into 2029. Yet risks linger in clinical translation.
8-K
Septerna doses first in SEP-631 trial
Septerna kicked off dosing in its Phase 1 trial of SEP-631, an oral small molecule targeting MRGPRX2 to curb mast cell activation in chronic spontaneous urticaria and related diseases. The randomized, placebo-controlled study in up to 150 healthy volunteers assesses safety, tolerability, pharmacokinetics, and pharmacodynamics via single- and multiple-ascending doses. This advances Septerna's GPCR platform toward oral options for unmet needs. Trial enrollment proceeds amid clinical risks.
ALT
Altimmune, Inc.
5.03-0.25
CRNX
Crinetics Pharmaceuticals, Inc.
48.61-0.71
GPCR
Structure Therapeutics Inc.
61.71-3.09
LPCN
Lipocine Inc.
3.15+0.00
LTRN
Lantern Pharma Inc.
3.33-0.04
MNPR
Monopar Therapeutics Inc.
71.47-3.65
MTSR
Metsera, Inc.
70.50-0.25
SEPSF
ASEP Medical Holdings Inc.
0.01+0.00
TCRT
Alaunos Therapeutics, Inc.
4.36+0.09
TERN
Terns Pharmaceuticals, Inc.
42.92-1.09